peripheral vascular disease

Claves para mejorar la productividad en la sala de cateterismo

Useful Predictor of Adverse Events in Complex PCI: BCIS CHIP Score

Among patients undergoing percutaneous coronary intervention (PCI), there is a need for risk stratification for successful planning and post procedural management. Risk stratification is paramount for effective decision making.  For a long time, the SYNTAX score has been the preferred tool for complex PCI patient risk assessment. However, it has important limitations, such as inter-observer...

The most read scientific articles in interventional cardiology in March on our website

Below, we share March’s most read scientific abstracts in interventional cardiology at solaci.org. ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable...

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TriClip: Tricuspid Regurgitation Dedicated Device

Severe tricuspid regurgitation (TR) is difficult to manage and is associated to high morbimortality.  Surgical repair is complex and not free from complications: its mortality rate ranges from 5 to 20% and depends on series, surgeon and center expertise. Edge-to-edge repair with clips has become a valid alternative to treat this disease, but most data...

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

COAPT: Promising 5-Year Outcomes

Secondary ischemic and non-ischemic mitral valve failure (SMR), produce left ventricle dilation, papillary muscle displacement, and impaired leaflet closure causing regurgitation. This will lead to ventricular function deterioration and bad prognosis.  Edge-to-edge mitral valve repair with MitraClip has been shown safe and effective to treat SMR in the short term, but its evolution at 5...

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory

Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling.  Randomized studies have shown that the use of Paclitaxel drug eluting stents (DES) reduces the number of new revascularizations (even though these studies compared mostly against conventional balloons, which is why we...

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVI

CTO: Trials vs. Real-World

Percutaneous coronary intervention of chronic total occlusions (CTO) is currently indicated for symptom improvement, as studies have inadequate randomization of data which hinders the assessment of hard outcomes. However, patient inclusion in randomized controlled trials has been challenging, especially for highly symptomatic and higher risk patients. This causes a selection bias in randomized studies on...

DISRUPT-PAD III: Seguimiento del tratamiento con IVL en territorio femoropoplíteo

DISRUPT-PAD III: Followup of IVL Treatment in Femoropopliteal Territory

Femoropopliteal segment calcification can generate complications for both preparation and execution of endovascular therapies for patients with peripheral artery disease. It can produce suboptimal vessel expansion associated to higher risk of dissection or perforation. These adverse effects can affect procedure durability in the long term.  Studies on the use of drug coated balloons to treat...

Nuevas estrategias en el territorio femoropoplíteo

IN.PACT Global: Follow Up of Real-Life Patient in Femoropopliteal Territory

Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized studies have shown their effectiveness and benefit in femoropopliteal territory, and even though the use of paclitaxel coated balloons has been called into question, a retrospective study including 168,553 patients was able to show paclitaxel coated balloons were...

SOLACI’s Year

2021 was filled with challenges for SOLACI. Many of the initiatives we started planning in 2020 saw the light and became a reality that strengthens our society’s reach and mission.  And not just that: we have also stepped up our efforts to expand and develop our traditional institutional activities always with the intent to add...

Top